Cargando…

High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

PURPOSE: Although programmed death-ligand 1 (PD-L1) expression is widely accepted as a predictive and prognostic biomarker in immunotherapy, its implications in lung cancer patients with driving mutations are still unclear. The objective of this study is to determine the association between PD-L1 ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Byung Woo, Chang, Boksoon, Lee, Seung Hyeun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445533/ https://www.ncbi.nlm.nih.gov/pubmed/32903896 http://dx.doi.org/10.2147/OTT.S271011

Ejemplares similares

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
por: Kwack, Won Gun, et al.
Publicado: (2021)

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
por: Sung, Ji-Youn, et al.
Publicado: (2022)

Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
por: Chang, Boksoon, et al.
Publicado: (2021)

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
por: Hwang, In Kyoung, et al.
Publicado: (2019)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
por: Cai, Yiran, et al.
Publicado: (2020)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR ‐mutated lung adenocarcinoma
por: Kunimasa, Kei, et al.
Publicado: (2023)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma
por: Li, Hong‐Shuai, et al.
Publicado: (2023)

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
por: Ding, Xiaosheng, et al.
Publicado: (2023)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Diagnostic and Predictive Values of (18)F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma
por: Hong, Il Ki, et al.
Publicado: (2020)

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2020)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma
por: Wang, Haiwei, et al.
Publicado: (2022)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2021)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma
por: van der Leest, Cor, et al.
Publicado: (2018)

Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2016)

High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma
por: Ishikawa, Masako, et al.
Publicado: (2020)

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2021)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
por: Li, Yuan-Yuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l4s71pk9ok0im1cb6cl16ihpq1